Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
EXEL

EXEL - Exelixis Inc Stock Price, Fair Value and News

$42.67-1.07 (-2.45%)
Market Closed

70/100

EXEL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

70/100

EXEL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$53.83

Target 3M

$46.48

Target 6M

$48.83

EXEL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EXEL Price Action

Last 7 days

-4.8%

Last 30 days

-5.9%

Last 90 days

9.6%

Trailing 12 Months

30.9%

EXEL RSI Chart

EXEL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EXEL Valuation

Market Cap

11.4B

Price/Earnings (Trailing)

16.88

Price/Sales (Trailing)

5

EV/EBITDA

68.54

Price/Free Cashflow

14.67

EXEL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$53.83

Target 3M

$46.48

Target 6M

$48.83

EXEL Fundamentals

EXEL Revenue

Revenue (TTM)

2.3B

Rev. Growth (Yr)

10.79%

Rev. Growth (Qtr)

5.19%

EXEL Earnings

Earnings (TTM)

677.9M

Earnings Growth (Yr)

64.09%

Earnings Growth (Qtr)

4.72%

EXEL Profitability

EBT Margin

4.94%

Return on Equity

31.37%

Return on Assets

24.01%

Free Cashflow Yield

6.82%

EXEL Investor Care

Buy Backs (1Y)

6.12%

Diluted EPS (TTM)

2.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20252.3B2.2B2.3B0
20241.8B2.0B2.1B2.2B
20231.7B1.7B1.8B1.8B
20221.5B1.6B1.6B1.6B
20211.0B1.2B1.3B1.4B
2020979.2M998.4M957.8M987.5M
2019855.6M909.8M956.1M967.8M
2018585.3M672.4M745.3M853.8M
2017256.9M319.7M410.0M452.5M
201643.2M71.5M123.8M191.5M
201529.6M31.0M34.6M37.2M
201426.6M21.3M22.1M25.1M
201338.6M42.7M34.8M31.3M
2012272.3M247.9M132.9M47.5M
2011178.7M163.3M237.1M289.6M
2010000185.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Exelixis Inc

EXEL
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
 CEO
 WEBSITEexelixis.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES1223

Exelixis Inc Frequently Asked Questions

EXEL is the stock ticker symbol of Exelixis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Exelixis Inc is 11.44 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check EXEL's fair value in chart for subscribers.

The fair value guage provides a quick view whether EXEL is over valued or under valued. Whether Exelixis Inc is cheap or expensive depends on the assumptions which impact Exelixis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EXEL.

As of Wed Jan 28 2026, EXEL's PE ratio (Price to Earnings) is 16.88 and Price to Sales (PS) ratio is 5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EXEL PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Exelixis Inc has provided 0.249 (multiply by 100 for percentage) rate of return.